Erythropoietin exerts an anti-inflammatory effect on the CNS in a model of experimental autoimmune encephalomyelitis

Brain Research

Volumn 952, Issue 1, 2002, Pages 128-134

  Agnello, Davide ^a   Bigini, Paolo ^a   Villa, Pia ^a,b   Mennini, Tiziana ^a   Cerami, Anthony ^c   Brines, Michael L ^c   Ghezzi, Pietro ^a,c  

^a MARIO NEGRI INSTITUTE FOR PHARMACOLOGICAL RESEARCH   (Italy)

^b CNR   (Italy)

^c Kenneth S Warren Institute   (United States)

Author keywords

Cytokine; Erythropoietin; Inflammation; Multiple sclerosis; Spinal cord

Indexed keywords

ANTIBODY; CD11B ANTIGEN; ERYTHROPOIETIN; GLIAL FIBRILLARY ACIDIC PROTEIN; INTERLEUKIN 6; MYELIN BASIC PROTEIN; TUMOR NECROSIS FACTOR;

ALLERGIC ENCEPHALOMYELITIS; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIINFLAMMATORY ACTIVITY; ARTHRITIS; ARTICLE; CENTRAL NERVOUS SYSTEM; CONTROLLED STUDY; DEMYELINATING DISEASE; DOSE CALCULATION; DRUG EFFECT; FEMALE; GLIA; IMMUNIZATION; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NONHUMAN; PRIORITY JOURNAL; RAT; RAT STRAIN; SCORING SYSTEM; SPINAL CORD; TIME;

ANIMALS; ANTI-INFLAMMATORY AGENTS; ARTHRITIS, EXPERIMENTAL; DISEASE MODELS, ANIMAL; ENCEPHALOMYELITIS, AUTOIMMUNE, EXPERIMENTAL; ERYTHROPOIETIN; FEMALE; INTERLEUKIN-6; MULTIPLE SCLEROSIS; RATS; RATS, INBRED LEW; SPINAL CORD; TUMOR NECROSIS FACTOR-ALPHA;

EID: 0037064261     PISSN: 00068993     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0006-8993(02)03239-0     Document Type: Article

References (26)

1. Agar N.S., Sadrzadeh S.M., Hallaway P.E., Eaton J.W. Erythrocyte catalase. A somatic oxidant defense? J. Clin. Invest. 77:1986;319-321.
2. Agnello D., Carvelli L., Muzio V., Villa P., Bottazzi B., Polentarutti N., Mennini T., Mantovani A., Ghezzi P. Increased peripheral benzodiazepine binding sites and pentraxin 3 expression in the spinal cord during EAE: relation to inflammatory cytokines and modulation by dexamethasone and rolipram. J. Neuroimmunol. 109:2000;105-111.
3. Baker D., Butler D., Scallon B.J., O'Neill J.K., Turk J.L., Feldmann M. Control of established experimental allergic encephalomyelitis by inhibition of tumor necrosis factor (TNF) activity within the central nervous system using monoclonal antibodies and TNF receptor-immunoglobulin fusion proteins. Eur. J. Immunol. 24:1994;2040-2048.
4. Brines M.L., Ghezzi P., Keenan S., Agnello D., de Lanerolle N.C., Cerami C., Itri L.M., Cerami A. Erythropoietin crosses the blood-brain barrier to protect against experimental brain injury. Proc. Natl. Acad. Sci. USA. 97:2000;10526-10531.
5. Brown J.M., Grosso M.A., Terada L.S., Beehler C.J., Toth K.M., Whitman G.J., Harken A.H., Repine J.E. Erythrocytes decrease myocardial hydrogen peroxide levels and reperfusion injury. Am. J. Physiol. 256:1989;H584-588.
6. Bryl E., Mysliwska J., Debska-Slizien A., Trzonkowski P., Rachon D., Bullo B., Zdrojewski Z., Mysliwski A., Rutkowski B. Recombinant human erythropoietin stimulates production of interleukin 2 by whole blood cell cultures of hemodialysis patients. Artif. Organs. 23:1999;809-816.
7. Eugster H.P., Frei K., Kopf M., Lassmann H., Fontana A. IL-6-deficient mice resist myelin oligodendrocyte glycoprotein-induced autoimmune encephalomyelitis. Eur. J. Immunol. 28:1998;2178-2187.
8. Furlan R., Brambilla E., Ruffini F., Poliani P.L., Bergami A., Marconi P.C., Franciotta D.M., Penna G., Comi G., Adorini L., Martino G. Intrathecal delivery of IFN-γ protects C57BL/6 mice from chronic-progressive experimental autoimmune encephalomyelitis by increasing apoptosis of central nervous system-infiltrating lymphocytes. J. Immunol. 167:2001;1821-1829.
9. Gill G.W., Frost J.K., Miller K.A. A new formula for a half-oxidized hematoxylin solution that neither overstains nor requires differentiation. Acta Cytol. 18:1974;300-311.
10. The Lenercept Multiple Sclerosis Study Group and The University of British Columbia MS/MRI Analysis Group . TNF neutralization in MS: results of a randomized, placebo-controlled multicenter study. Neurology. 53:1999;457-465.
11. Hebert L.A., Birmingham D.J., Shen X.P., Brandt J.T., Sedmak D.D., Dillon J.J. Effect of recombinant erythropoietin therapy on autoimmunity in systemic lupus erythematosus. Am. J. Kidney Dis. 24:1994;25-32.
12. Hisahara S., Araki T., Sugiyama F., Yagami K., Suzuki M., Abe K., Yamamura K., Miyazaki J., Momoi T., Saruta T., Bernard C.C., Okano H., Miura M. Targeted expression of baculovirus p35 caspase inhibitor in oligodendrocytes protects mice against autoimmune-mediated demyelination. EMBO J. 19:2000;341-348.
13. Houser C.R., Barber R.P., Crawford G.D., Matthews D.A., Phelps P.E., Salvaterra P.M., Vaughn J.E. Species-specific second antibodies reduce spurious staining in immunocytochemistry. J. Histochem. Cytochem. 32:1984;395-402.
14. Juul S.E., Anderson D.K., Li Y., Christensen R.D. Erythropoietin and erythropoietin receptor in the developing human central nervous system. Pediatr. Res. 43:1998;40-49.
15. Kassiotis G., Pasparakis M., Kollias G., Probert L. TNF accelerates the onset but does not alter the incidence and severity of myelin basic protein-induced experimental autoimmune encephalomyelitis. Eur. J. Immunol. 29:1999;774-780.
16. Magnus T., Chan A., Grauer O., Toyka K.V., Gold R. Microglial phagocytosis of apoptotic inflammatory T cells leads to down-regulation of microglial immune activation. J. Immunol. 167:2001;5004-5010.
17. Mendel I., Katz A., Kozak N., Ben-Nun A., Revel M. Interleukin-6 functions in autoimmune encephalomyelitis: a study in gene-targeted mice. Eur. J. Immunol. 28:1998;1727-1737.
18. Mittelman M., Neumann D., Peled A., Kanter P., Haran-Ghera N. Erythropoietin induces tumor regression and antitumor immune responses in murine myeloma models. Proc. Natl. Acad. Sci. USA. 98:2001;5181-5186.
19. Okuda Y., Sakoda S., Bernard C.C., Fujimura H., Saeki Y., Kishimoto T., Yanagihara T. IL-6-deficient mice are resistant to the induction of experimental autoimmune encephalomyelitis provoked by myelin oligodendrocyte glycoprotein. Int. Immunol. 10:1998;703-708.
20. Okuda Y., Sakoda S., Fujimura H., Yanagihara T. The effect of apoptosis inhibitors on experimental autoimmune encephalomyelitis: apoptosis as a regulatory factor. Biochem. Biophys. Res. Commun. 267:2000;826-830.
21. Penkowa M., Hidalgo J. Metallothionein I+II expression and their role in experimental autoimmune encephalomyelitis. Glia. 32:2000;247-263.
22. Reder A.T., Thapar M., Jensen M.A. A reduction in serum glucocorticoids provokes experimental allergic encephalomyelitis: implications for treatment of inflammatory brain disease. Neurology. 44:1994;2289-2294.
23. Siren A.L., Fratelli M., Brines M., Goemans C., Casagrande S., Lewczuk P., Keenan S., Gleiter C., Pasquali C., Capobianco A., Mennini T., Heumann R., Cerami A., Ehrenreich H., Ghezzi P. Erythropoietin prevents neuronal apoptosis after cerebral ischemia and metabolic stress. Proc. Natl. Acad. Sci. USA. 98:2001;4044-4049.
24. Van Dam A.M., Bauer J., Man A.H.W.K., Marquette C., Tilders F.J., Berkenbosch F. Appearance of inducible nitric oxide synthase in the rat central nervous system after rabies virus infection and during experimental allergic encephalomyelitis but not after peripheral administration of endotoxin. J. Neurosci. Res. 40:1995;251-260.
25. van der Meide P.H., de Labie M.C., Ruuls S.R., Groenestein R.J., Botman C.A., Olsson T., Dijkstra C.D. Discontinuation of treatment with IFN-beta leads to exacerbation of experimental autoimmune encephalomyelitis in Lewis rats. Rapid reversal of the antiproliferative activity of IFN-beta and excessive expansion of autoreactive T cells as disease promoting mechanisms. J. Neuroimmunol. 84:1998;14-23.
26. Yoshimura A., Misawa H. Physiology and function of the erythropoietin receptor. Curr. Opin. Hematol. 5:1998;171-176.